Invesco S&P SmallCap Consumer Staples ETF (PSCC)

NASDAQ: PSCC · Real-Time Price · USD
36.21
+0.77 (2.17%)
At close: Jul 10, 2026, 4:00 PM EDT
36.96
+0.75 (2.07%)
After-hours: Jul 10, 2026, 6:28 PM EDT
Assets$32.83M
Expense Ratio0.29%
PE Ratio14.98
Shares Out1.04M
Dividend (ttm)$0.60
Dividend Yield1.67%
Ex-Dividend DateJun 22, 2026
Payout FrequencyQuarterly
Payout Ratio24.99%
Volume12,649
Open35.77
Previous Close35.44
Day's Range35.75 - 36.34
52-Week Low30.60
52-Week High36.66
Beta0.61
Holdings29
Inception DateApr 7, 2010

About PSCC

Fund Home Page

The Invesco S&P SmallCap Consumer Staples ETF (PSCC) is an exchange-traded fund that mostly invests in consumer staples equity. The fund tracks a market-cap-weighted index of consumer staples stocks selected from the S&P SmallCap 600. PSCC was launched on Apr 7, 2010 and is issued by Invesco.

Asset Class Equity
Category Consumer Defensive
Stock Exchange NASDAQ
Ticker Symbol PSCC
ETF Provider Invesco
Index Tracked S&P Small Cap 600 Capped Consumer Staples

Top 10 Holdings

63.55% of assets
NameSymbolWeight
Conagra Brands, Inc.CAG11.70%
Lamb Weston Holdings, Inc.LW10.11%
PriceSmart, Inc.PSMT7.60%
The Campbell's CompanyCPB6.87%
Cal-Maine Foods, Inc.CALM6.01%
The Vita Coco Company, Inc.COCO4.78%
The Chefs' Warehouse, Inc.CHEF4.34%
WD-40 CompanyWDFC4.26%
Freshpet, Inc.FRPT4.12%
Interparfums, Inc.IPAR3.75%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Jun 22, 2026$0.11584Jun 26, 2026
Mar 23, 2026$0.13003Mar 27, 2026
Dec 22, 2025$0.14135Dec 26, 2025
Sep 22, 2025$0.21675Sep 26, 2025
Jun 23, 2025$0.20093Jun 27, 2025
Mar 24, 2025$0.17199Mar 28, 2025
Full Dividend History

Performance

PSCC had a total return of 8.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.87%.

News

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies

PARIS--(BUSINESS WIRE)-- #adc--One Biosciences receives Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop first single-cell assay for antibody-drug conjugates therapies.

18 days ago - Business Wire

How To Avoid The Worst Sector ETFs 3Q23

I leverage my firm's data to identify three red flags you can use to avoid the worst ETFs.

3 years ago - Forbes